
Advancing Precision in Endometrial Cancer: Molecular classification and its impact on prognosis and treatment. Are we ready?

Barbara Goff, MD Gynecologic Oncology Chair, Department of Obstetrics & Gynecology Surgeon-in-Chief, University of Washington



2013 Integrated genomic characterization of endometrial cancer. TCGA

- Identified 4 molecular classifications
 - POLE -7% Ultramutated often high grade
 - MMRd 30% Germline + Somatic loss, PTEN, PIK3CA
 - P53 abnormal 20% High grade and serous
 - NSMP 40% ER PR positive




sumber figh turnous have the poolest autcome, Briage adapted from Kandoth et al., 2013

Validated in over 4000 pts

Cancer Genome Atlas Network Integrated genomic characterization of endometrial cancer. Nature 2013

Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE)



Talhouk et al Cancer 2017

Molecular classification predicts response to radiotherapy in the randomized PORTEC1 and PORTEC-2 trials for early stage endometriod endometrial cancer

• PORTEC 1 n=714

-EBRT vs Observation

-Grade 1 or 2 with outer half myoinvasion

-Grade 2 or 3 up to middle third invasion

• PORTEC 2 n=427 HIR

- EBRT vs VBT
- Stage 1B > age 60, grade 3
- Stage 1C >age 60 grade 1-2
- Stage IIA, except grade 3 with deep myoinvasion

Horewege et al. PORTEC Study Group JCO 2023


Molecular Analysis of PORTEC 1&2

880 patients POLE 7.5% (n=66) dMMR 28.1% (n=247) p53 8% (n=70) NSMP 56.5% (n=497)

- POLE: no recurrence regardless of radiation
- dMMR: EBRT or VBT not associated with improved RFS 94.2% EBRT, 94.2% VBT, 90.3% Observation. (p= .74)
- P53 abnormal: EBRT improves RFS 96.9% EBRT, 64.3% VBT, 72.2% Observation. (p= .048)
- NSMP: Local regional control better with EBRT or VBT 98.3% EBRT, 96.2% VBT, 87.7% Observation. (p< .0001)

The molecular classification of EC predicts response to radiation in stage I EEC and may guide treatment decisions

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy



Leon-Castillo et al. JCO 2020 PORTEC consortium

Molecular Classification of PORTEC III


High risk disease (stage III and/or high risk histology): EBRT vs CTRT

_		5 year RFS
POLE	12%(51)	98%
MMRd	33%(137)	72%
P53	23%(93)	48%
NSMP	32%(129)	74%

5 year RFS			
EBRT	CTRT	р	
97%	100%	.64	
76%	68%	.42	
36%	59%	.019	
68%	80%	.24	
	EBRT 97% 76% 36%	EBRTCTRT97%100%76%68%36%59%	EBRTCTRTp97%100%.6476%68%.4236%59%.019

Her 2 neu

- Expressed in 30% of Uterine Serous Tumors
- Poor prognostic factor associated with worse survival
- Trial of pts with 3+ Her2neu or 2+ with FISH amplification randomized to paclitaxel/carbo vs paclitaxel/carbo/transtuzumab with with maintenance showed the addition of transtuzumab improved OS




Fader et al. JCO 2018


2023 FIGO Endometrial Cancer Staging


Stage designation	Molecular findings in patients with early endometrial cancer (stages I and II after surgical staging)
Stage IAm ^{POLEmut}	<i>POLEmut</i> endometrial carcinoma, confined to the uterine corpus or with cervical extension, regardless of the degree of LVSI or histological type
Stage IICmp ^{53abn}	p53abn endometrial carcinoma confined to the uterine corpus with any myometrial invasion, with or without cervical invasion, and regardless of the degree of LVSI or histological type


Mutated p53 portends improvement in outcome when bevacizumab is combined with chemo. An NRG study

- GOG study 86P
- Stage III/IV/recurrent
- PC bev, PC temsirolimus, ixabepilone/C bev
- 243 has p53 mutational analysis done
- 44% mp53 and 56% wtp53
- Those with p53 mutation had worse prognosis PFS 10 vs 12 month
- PFS bev vs temsirolimus 12.5 vs 8.2 in mp53 (HR 0.48 Cl 0.31-0.75)
- PFS and OS for wtp53 no difference











MMRd/MSIh Endometrial cancer

- Initial indication for immune checkpoint inhibitors (pembrolizumab, dostarlimab) for second line therapy.
- 2 trials, GY 2018 and RUBY evaluated addition of PD-1 inhibition in first line treatment followed by 2-3 years of maintenance treatment



RUBY Trial with dostarlimab



Mirza et al. NEJM 2023

DUO-E: durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab +/- olaparib

Control arm: C/T/D followed by placebo Durvalumab arm: C/T/D followed by durvalumab maintenance Durvalumab Olaparib arm: C/T/D followed by durvalumab and Olaparib maintenance

MMRd Cohort PFS 18mo

Westin et al JCO 2023

67.9% O+D 62% D 43.4% Control


- The addition of Olaparib did not substantially improve PFS outcomes
- HR for PFS C vs D 0.42 (0.22 -0.80) D-O vs C 0.41 (0.21-0.75)

MMRp Cohort PFS 15 mo O+D 9.9 mo D 9.7mo C


Olaparib did improve PFS in MMRp cohort HR 0.57 (0.44-0.73)

Other molecular targeted therapies

- PTEN and PI3K/AKT/mTOR pathway: MTOR inhibitors PI3KCA inhbitors
- KRAS, BRAF, NRAS: MEK inhibitors
- HRD pathway, somatic Rad51 mutations: PARPi
- ARID1A :EZH2 inhibitors and PARPi
- CTNNB1 mutations can lead to activation of VEGF: Bev with chemo
- FGFR2 mutations: FGFR inhibitors
- ER/ PR: Hormones, CDK4/6 inhibitors, Evirolimus and letrozole
- Her2neu: Trastuzumab and ADCs targeting Her2neu
- dMMR MSIh: PDL-1 inhibitors
- pMMR MSIs: Pembro with lenvatatinib



Ongoing studies: RAINBO



Conclusion

Molecular profiling in endometrial cancer is important for prognosis and treatment As of 2024

- POLE: retrospective studies suggest that de-escalation of treatment is possible. Ongoing studies evaluating observation only in these patients
- P53 abn: More aggressive treatment is needed. EBRT vs VBT and chemo possibly w bev
- dMMR: unclear if radiation is beneficial in HIR but addition of PD-L1 is essential in advanced and recurrent disease to chemo
- NSMP: Vaginal Brachytherapy beneficial in HIR
- Her 2 neu: Addition of trastuzumab is associate with improvement in OS